Philippines FDA eServices Portal and Submission Channels

1. Key takeaways

The Philippines currently runs two submission channels in parallel. All initial CMDN applications for Class A devices must be filed through the FDA eServices portal at eservices.fda.gov.ph from 10 March 2025, and the old ePortal system stopped accepting them on the same date. CMDR applications for Class B, C and D devices continue to be filed through the designated mailbox at cdrrhr-productregistration@fda.gov.ph. Registration status can be checked publicly on the FDA Verification Portal at verification.fda.gov.ph.

The split is administrative rather than technical, but it creates two different working routines inside the same company. A manufacturer holding both Class A and Class B products is dealing with a portal that generates its own payment order and with a mailbox that does not, so progress tracking, evidence of submission and fee reconciliation all follow different paths for each product line. Consistency in the project register therefore depends on internal discipline rather than on the system, because no single dashboard covers both channels at once, and a status report assembled from the portal alone will silently omit every Class B, C and D file in the portfolio.

• Class A initial CMDN: eServices portal only, from 10 March 2025.
• Class B, C and D CMDR: designated mailbox, not the portal.
• Applications already filed in the old ePortal continue to be processed without refiling.
• Switching an existing application to the portal requires a new payment, with earlier fees neither credited nor refunded.
• The order of payment issued by the portal is the only reliable fee record while the fee rules are in transition.

2. Legal basis

The operative announcement is FDA Advisory No. 2025-0189, which followed two pilot advisories in 2024. The underlying authorisation framework remains AO No. 2018-0002, and the portal covers only Class A devices because that is the scope of the authorisation it supports. The verification portal is separate from both submission channels and is a public register rather than a filing system.

The two 2024 advisories were pilots for the same transition rather than separate schemes. Read together with the 2025 advisory, they show a staged move to the portal: a pilot period, a date on which the new channel becomes mandatory for initial Class A applications, and a parallel instruction that keeps Class B, C and D on email for the time being. The sequence matters when a file was prepared during the pilot and submitted after the mandatory date, since the channel that applied at preparation is not necessarily the channel that applies at submission.

3. Expert insights

Insight one: the channel difference follows from product complexity, not administrative neglect.

The eServices portal covers Class A first because the Class A document set is comparatively standardised and lends itself to a workflow. The CSDT file for Class B, C and D is large, attachment-heavy, and the review involves several rounds of technical exchange, which is why it is still handled by email. Understanding the reason matters for planning: the electronic experience of a Class A filing should not be used to set expectations for the timeline of a Class B filing, because the two are processed through genuinely different mechanisms.

Insight two: the order of payment is the only reliable fee evidence.

At a moment when the fee schedule is between an old order and a new one, any figure copied from a secondary source may be wrong. Our operating rule is that the order of payment issued by the eServices portal governs, and payment is made against that order. It is also the only dependable evidence in a fee dispute, because it originates from the system that will apply the credit rather than from a published table that may no longer be in force.

Insight three: old ePortal applications do not migrate automatically, and fees are not returned.

FDA Advisory No. 2025-0189 states that Class A applications already submitted in ePortal will continue to be processed and do not need to be refiled. However, where an applicant chooses to move to the eServices portal, a separate payment is required, and fees already paid in ePortal are neither credited nor refunded. This is a clear cost warning. Confirm the channel before submitting, and do not pay twice for the same application simply because the newer system appears more convenient.

Insight four: the verification portal is public infrastructure for post-market compliance.

FDA public health warnings repeatedly direct the public and procurement officers to verify registration numbers through the Verification Portal, and the number formats include DVR-xxx, MDR-xxx, IVDR-xxx and RR-xxx. For a manufacturer this means the registration status of the product is publicly searchable after launch. Once a certificate expires or is cancelled, the change is visible immediately at the points where it matters most: tender qualification and customs clearance.

4. Practical recommendations

• Confirm the channel in force before every submission. Channel rules change with FDA advisories, so check the latest advisory rather than following the routine used on the previous filing. A filing sent to a disabled channel is not processed and may lose queue position.
• Manage projects by product tier. Where a company holds both Class A and Class B, C or D lines, the two require different submission and tracking routines, and the project register should record them separately so that a portal deadline is never confused with a mailbox deadline.
• Self-check the Verification Portal after launch. Search your own products quarterly and confirm that the certificate, product name and label information all agree. Discrepancies are easier to correct before a tender or a customs query exposes them.
• Retain every order of payment and acknowledgement. The payment order is the evidence for a fee dispute and for progress enquiries, and it is also the document an auditor will ask for when reconciling regulatory spend.

5. Verification checklist

• □ Confirm that the channel matches the class: Class A to eServices, Class B, C and D to the designated mailbox.
• □ Confirm the current advisory position in the announcements section of the FDA website.
• □ Confirm how the order of payment is generated through the eServices portal.
• □ Confirm the handling status of any application already filed in the old system, which continues to be processed.
• □ Confirm that registration status is retrievable at verification.fda.gov.ph.
• □ Confirm the registration number prefix: DVR, MDR, IVDR or RR.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including the Philippines. Our team prepares CMDN/CMDR dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the FDA Philippines, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com